Quarterly Results

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

• Phase I/2a clinical trials initiated: VMT-𝛼-NET for neuroendocrine tumors, and VMT01 for melanoma…

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

* Additional CDMO capabilities added to increase availability of clinical trial product in the US
* Phase I/IIa studies are initiating in the first half of 2023 for VMT- 𝛼-NET for neuroendocrine tumors and VMT-01 for melanoma

Perspective Therapeutics
Linkedin-in Youtube Vimeo
Perspective Therapeutics
Linkedin-in Youtube Vimeo

Company

Brachytherapy

Theranostics

Newsletter

Want to keep up-to-date on news and information?

Sign up
Sign up

Company

Newsletter

Want to keep up-to-date on news and information?

Sign up
Sign up

©2023. All rights reserved. Terms & Privacy | Privacy Policy

Scroll to top